194results about How to "Antigenic" patented technology

The invention relates to a medical flocking hemostasis material for stopping bleeding and protecting arteries, veins and wounds of tissues, application of the medical flocking hemostasis material and a method for preparing the medical flocking hemostasis material. The medical flocking hemostasis material comprises a flocking layer and a base layer, the flocking layer is used as a wound contacting layer and made of functional fibers, and the functional fibers are fixed on the upper surface of the base layer in a flocking method. The flocking method comprises a mechanical flocking method and an electrostatic flocking method. The medical flocking hemostasis material can be used for stopping bleeding and protecting the arteries, the veins and the wounds of the tissues, and further can be used as a medicine slow-release carrier. The invention further discloses method for controlling bleeding of the arteries, bleeding of the veins and bleeding of the wounds of the tissues by the aid of the medical flocking hemostasis material. Compared with a hemostasis material in the prior art, the medical flocking hemostasis material has the advantages that a hemostasis performance, comfortableness and the like are greatly improved.

The invention relates to a medical compound micropore polysaccharide and application in hemostasis on wound surface bleeding areas of various wounds and operation tissues. The medical compound micropore polysaccharide is prepared by adopting a method with the following steps: (1) preparing starch fluid; (2) preparing carboxymethyl chitosan solution; (3) mixing the starch fluid and the carboxymethyl chitosan solution, and adding dispersant and emulsifier into the mixture; (4) emulsifying, crosslinking and co-polymerizing; and (5) refining, drying, packing and sterile treatment. The invention also discloses application of the medical compound micropore polysaccharide in preparing a hemostasis medicament used for the wound surface bleeding areas of wounds and operation tissues. The medical compound micropore polysaccharide of the invention has the following characteristics: 1, the hemostasis time is short, namely the hemostasis is generally finished in 3 to 5 minutes; 2, the medical compound micropore polysaccharide has no antigenicity, has polysaccharide components, and has no protein or immune reaction; 3, the medical compound micropore polysaccharide can be fully degraded and absorbed in vivo; 4, the medical compound micropore polysaccharide is a sterile product and is convenient to use by opening; and 5, the tissue reaction is light. Therefore, the medical compound micropore polysaccharide is a comparatively ideal surgical hemostasis product.

The invention relates to a preparation technique of crosslinked hyaluronic acid gel preparation, characterized in that divinylsulphone reacts with hydroxyl group of hyaluronic acid to form ether linkage. The steps are that the raw material of hyaluronic acid being put into container and dissolving in alkali reagent; stirring to make it thoroughly dissolve; mixing the alkaline hyaluronic acid solution and divinylsulphone in container to form crosslinked hyaluronic acid gel clot; adding substance riched in hydroxyl groups into the reaction solution; extracting the crosslinked hyaluronic acid gel clot and putting it into agitator to stir; and then crosslinked hyaluronic acid gel becoming micro grained. The advantages thereof are that the gel preparation is suitable for injection in vivo, with long residence timen in humans and good filling effect.

The construction process of skin tissue engineering rack containing epidermal growth factor with fetus calf or ox tendo achillis as basic material includes dewatering, defatting, primary enzyme treatment to reduce the covalent bond among tissue fibers, dialysis, secondary enzyme treatment to remove antigenic determinant, dissolving with acetic acid to obtain no-antigenicity collagen solution and collagen sponge film, soaking in propanetriol to adsorb, drying, mixing water solution of heparin and acetic acid, water solution of epidermal growth factor and propanetriol wetted collagen sponge film, and final freeze drying. The rack has no antigenicity, high strength, high flexibility, convenient operation implantation, no toxicity to wound, and capacity of inducing wound cell growth and promoting wound healing.

The invention provides a crosslinking hyaluronic acid gel and its preparation method. The method is characterized in that divinylsulfone is combined with polyethylene glycol for generating a novel cross-linking agent at first, the novel cross-linking agent is reacted with a hyaluronic acid molecule for producing a crosslinking hyaluronic acid gel. The crosslinking sodium hyaluronate gel obtained in the invention has good biological compatibility and longer half life period, and the particle is small and uniform, and is suitable for beautifying shaping, tissue filling, bone articular lubrication or medicine sustained-release preparation and the like.

The present invention relates to construction process of artificial skin containing human bone marrow mesenchymal stem cell. Skin tissue engineering rack is first constructed with fetus calf or ox tendo achillis as basic material, collagen sponge film through twice enzyme treatments and the mixture of heparin and epidermal growth factor; and human bone marrow mesenchymal stem cell obtained via purifying human bone marrow blood is implanted on two sides of the rack to constitute the artificial skin with bone marrow mesenchymal stem cell on the two sides of and in the internal of the rack. The artificial skin has no antigenicity, high strength, high flexibility, no toxicity to wound, and capacity of inducing wound cell growth and promoting wound healing.

The invention relates to cross-linked sodium hyaluronate and a preparation method and application thereof. The cross-linked sodium hyaluronate is prepared from raw materials, including sodium hyaluronate, an inorganic salt and a cross-linking agent. The preparation method comprises the steps: dissolving a certain amount of sodium hyaluronate in an alkaline solution with the pH value of 7.5 to 9.0, then, adding a certain amount of inorganic salt into the solution, and carrying out stirring until the inorganic salt is completely dissolved; heating the solution to the temperature of 20 DEG C to 60 DEG C, then, slowly dripping a certain volume of cross-linking agent solution into the solution, carrying out stirring, and carrying out a reaction for a period of time while carrying out heat preservation; adjusting the pH to 7.1 to 7.5 with acid, carrying out balancing for 1 to 2 hours, then, carrying out precipitation with ethanol or an ethanol solution, so as to obtain lumpy solids, i.e., the cross-linked sodium hyaluronate. By the method provided by the invention, the cross-linking efficiency of the cross-linked sodium hyaluronate can be increased, the reaction yield can be increased, side reactions can be reduced, and the residual of the cross-linking agent can be reduced; the prepared cross-linked sodium hyaluronate is safe and non-toxic, is good in stability, long in in-vivo retention time and good in filling effect and is applicable to in-vivo injection.

The invention relates to a preparation method and a refining method of medical hemostatic polysaccharide starch. With pretreated potato starch as a raw material and epichlorohydrin as a crosslinking agent, a microsphere adopting a three-dimensional network structure is synthesized by an emulsifying and crosslinking technology. The medical hemostatic polysaccharide starch is high in biocompatibility; the medical hemostatic polysaccharide starch is full with wrinkles on the surface, so that the particle surface area is increased, the water absorbing rate is significantly improved and the hemostatic time is greatly reduced; the medical hemostatic polysaccharide starch is especially applicable to large-area blood seepage, deep bleeding, and bleeding at a part difficult to reach by operative procedures.

The present invention belongs to the field of medicine technology. The Carbazochrome liquid contains Carbazochrome 0.002-0.5 wt%, antioxidant 0-10 wt%, osmotic pressure regulator 0.8-75 wt%, and injection water 20-99.1 wt%. The preparation process of the Carbazochrome liquid includes dissolving osmotic pressure regulator with partial injection water in a compounding tank; adding injection level active carbon through heating and stirring for adsorption for 30 min; filtering and decarbonizing with titanium rod and adding rest injection water to obtain the solution I; dissolving Carbazochrome and antioxidant in solution I, adding injection level active carbon for adsorption for 30 min, filtering and decarbonizing with titanium rod, regulating pH value, fine filtering, detecting, packing in bottle, disinfecting and other steps. The medicine is used in intravenous transfusion for treating various hemorrhage diseases.

The invention provides vagina pH buffer antibacterial gel, a preparation method thereof, and a using method thereof. The gel mainly comprises the components of polycarbophil, carbomer, ethylenediamine tetraacetic acid disodium, chitosan, glycerol, triethanolamine, methyl parahydroxybenzoats and deionized water. By using the weak acidity of polycarbophil and the antibacterial performance of chitosan, the gel can eliminate the source of recurrence of vagina inflammatory diseases and recovers the self-cleaning ability of the vagina. The gel is free from antigen performance, allergy and irritation, and convenient to use, and tissue reaction is avoided.

The invention provides a method for preparing a biological scaffold by 3D printing. The method comprises the steps of grinding allogeneic bones or heterogeneous bones at a low temperature in a freezing grinder to obtain a printing material, modeling 3D printing with the aid of a computer, and then performing post treatment in a genipin solution. The prepared biological scaffold has good biological compatibility, and the bone graft material does not have toxicity, rejection, mutagenicity or antigenicity in vivo, and does not disturb bone and tissue regeneration; the prepared biological scaffold can be gradually degraded and absorbed and replaced by autologous bone tissues, can bear the pressure close to 20MPa with normal bone cortex, and has good initial mechanical properties; and the elastic modulus is gradually reduced, stress shielding is avoided, fracture, collapse and loosening of implants in the long-term healing process are avoided, bone fusion can be accelerated, and the implants can be finally completely converted into autologous bone tissues.

The invention discloses a structure and a preparation method of a multifunctional woman pelvic biological repair plate. The biological repair plate takes natural biomembranes as raw material, is processed through a series of biochemical technology, increases the stability greatly, and is made through remachining shaping and activity-modifying. The stability of the material is high, the biocompatibility is good, the ingrowth for autologous nerve structures of a patient can be induced, and the supporting and fixing functions of the autologous nerve structures can be served. The morphological structure of the multifunctional woman pelvic biological repair plate comprises a head, double wings and a bosom body, and likes a tailless mosquito hawk, as shown in an attached drawing. The structure is designed according to years of clinical experience of an inventer, the adaptability is wide, the practicability is strong, and the multifunctional woman pelvic biological repair plate can be used in multiple situations such as posterior vaginal wall prolapse, musculus levator ani laceration, uterosacral ligament slack, rectovaginal diaphragm defect, rectovaginal fistula repair, vaginal contraction, etc.

Antibodies or functional fragments thereof that have agonistic or antagonistic effects on CD40.

The invention relates to bovine lactoferricin and a preparation method thereof. Bovine lactoferricin (Lfcin B) is 25 amino acid residues hydrolyzed from a bovine lactoferrin (BLF) N-terminal (17-41) by pepsin, and has a molecular weight of approximately 3.1kd. The preparation method comprises the steps of: (2) recombinant expression vector construction; (2) fusion protein expression induction; and (3) protein separation and purification. Bovine lactoferricin has the advantages that: Lfcin B has the highest activity among all the Lfcins, and an antibacterial effect 400 times that of bovine lactoferrin, such that Lfcin B can play an important role in gastrointestinal tracts.

A histo-enigineered esophagus is disclosed, and it contains a dual-layer structure of epithelial layer and dermis layer constructed by scaffold material and seed cells. The vascular endothelial cellsin the dermis layer directly take part in the creation of capillary network. Two revascularization methods are used for quickly communicating with the blood supply channel of receptor.

The invention relates to the molecular immunology field. Although the existing foot-and-mouth disease weak poison vaccines and inactivated vaccines and other routine vaccines have good immunogenicity, but the vaccines have some unsafe factors such as reversion of virulence, incomplete virus blanching, the escape of live-virus from a preparation factory and the like so that people are motivated to find a more safe and effective FMD vaccine. In the molecular mimic peptide invention, phage display techniques are used to sieve effective FMDV epitopes to provide an O-type foot and mouth disease virus antigen epitope molecular mimic peptide and the invention also provides an application thereof in preparing immunogen and swine foot-and-mouth disease epitope peptide vaccine. The FMDV epitope peptide vaccine using the molecular mimic peptide of the invention has the antigenicity of target molecule without toxicity, is very safe and has low mass production cost and good economic effect and social effect.

The invention discloses a recombinant novel coronavirus COVID-19S-RBD protein and a preparation method and application thereof. The preparation method comprises the steps that an artificially synthesized S-RBD fusion protein gene is constructed into an escherichia coli expression system, and then the soluble purified recombinant COVID-19S-RBD protein with high expression quantity and antigenicityis obtained through a special inclusion body renaturation technology. The preparation method of the recombinant protein is easy and convenient to operate, low in production cost and high in efficiency, and the prepared recombinant protein can be used for preparing a reagent strip for detecting new coronavirus; the using effect of the reagent strip is verified by the preparation method, the detection result is accurate, the efficiency is high, the result is popular and easy to understand, and the preparation method is particularly suitable for rapid screening of the new coronavirus of a large number of people.

The preparation process of cell-eliminating pig corium substrate includes sustained vibration of the corium substrate in 0.5 mol/L NaOH solution compounded with thrice distilled water, rinsing with thrice distilled water and balanced phosphate salt solution separately, freeze drying, packing and sterilizing. The cell-eliminating pig corium substrate is used as the in vitro corium culturing rack in composite skin preparing tissue engineering process, and the preparation process includes coating the corium substrate with acetic acid dissolved type-I ox collagen, regulating pH to 7.0-7.4, soaking subsequently in balanced phosphate salt solution and no serum culture medium, inoculating passage epidermal cell, and no serum culture inside a CO2 hatcher. The tissue engineering composite skin is used as human skin substitute.

The invention discloses a paper additive and a preparation method. During preparation, the paper additive comprises raw materials in parts by weight as follows: 0.6-6 parts of an antibacterial agent, namely, polyhexamethylene guanidine hydrochloride, 1-4 parts of carboxymethyl chitosan, 0.4-2 parts of a condensing agent, 0.1-0.5 parts of an activating agent and 0.05-0.2 parts of a cross-linking agent. The preparation method comprises steps as follows: the carboxymethyl chitosan is dissolved in water, then the pH value is adjusted to range from 5 to 5.5 with hydrochloric acid, the condensing agent and the activating agent are added to the mixture for activation, the antibacterial agent, namely, the polyhexamethylene guanidine hydrochloride, is added for a reaction, an obtained reaction liquid is subjected to suction-filtration, washing, drying and crushing and then evenly mixed with the cross-linking agent, namely, N,N-dimethyl bisacrylamide, an obtained mixture is dissolved in deionized water, and the paper additive is obtained. The paper additive has the advantages that the paper additive is broad in spectrum, high in efficiency, low in toxicity, free of drug resistance, high in antibacterial endurance and the like in the antibacterial aspect and has the advantages that the paper additive is capable of significantly enhancing the paper strength, non-toxic and harmless to human bodies and the like in the enhancing aspect.